Mesothelin Expression in Patients with High-Grade Serous Ovarian Cancer Does Not Predict Clinical Outcome But Correlates with CD11c + Expression in Tumor
ConclusionOur results show that MSLN expression does not correlate with clinical outcome. The impact of the correlation between MSLN and CD11c+ cells on immunotherapy outcome should be further explored. (Source: Advances in Therapy)
Source: Advances in Therapy - October 29, 2020 Category: Drugs & Pharmacology Source Type: research

Evaluation of Patients with Insufficient Efficacy and/or Tolerability to Triptans for the Acute Treatment of Migraine: A Systematic Literature Review
ConclusionsIrrespective of the methodology or definition used to identify people with insufficient efficacy and/or tolerability to triptans, study results support the assertion that a high unmet need remains for effective acute treatment of migraine. (Source: Advances in Therapy)
Source: Advances in Therapy - October 29, 2020 Category: Drugs & Pharmacology Source Type: research

Baseline Demographics and Clinical Characteristics Among 3471 US Patients Hospitalized with COVID-19 and Pulmonary Involvement: A Retrospective Study
ConclusionsAmong US patients primarily from the South and Midwest hospitalized with COVID-19 and pulmonary involvement, the most common comorbidities were hypertension, diabetes, hyperlipidemia, and obesity. Differences observed between African American and White patients should be considered in the context of the complex factors underlying racial disparities in COVID-19. (Source: Advances in Therapy)
Source: Advances in Therapy - October 29, 2020 Category: Drugs & Pharmacology Source Type: research

Clinical Characteristics of a Non-Alcoholic Fatty Liver Disease Population Across the Fibrosis Spectrum Measured by Magnetic Resonance Elastography: Analysis of Screening Data
ConclusionsThere was considerable variation and overlap in clinical characteristics across the spectrum of liver stiffness. Although groups with high MRE values generally included more subjects with T2D and obesity, and had higher age and concentrations of liver enzymes, the clinical characteristics did not strongly correlate with MRE scores in this population.Trial RegistrationRegistered on Clinicaltrials.gov on November 29, 2017 (NCT03357380). (Source: Advances in Therapy)
Source: Advances in Therapy - October 29, 2020 Category: Drugs & Pharmacology Source Type: research

Consequences of Supraphysiological Dialysate Magnesium on Arterial Stiffness, Hemodynamic Profile, and Endothelial Function in Hemodialysis: A Randomized Crossover Study Followed by a Non-Controlled Follow-Up Phase
ConclusionsIncreasing dialysate magnesium improves vascular stiffness in subjects undergoing maintenance hemodialysis. The present findings merit a larger trial to evaluate the effects of 0.75  mmol/L D-Mg2+ on major clinical outcomes.Trial RegistrationThe study was retrospectively registered on the ISRCTN registry (ISRCTN 74139255) on 18 June 2020. (Source: Advances in Therapy)
Source: Advances in Therapy - October 29, 2020 Category: Drugs & Pharmacology Source Type: research

The Frequency of Ovarian Hyperstimulation Syndrome and Thromboembolism with Originator Recombinant Human Follitropin Alfa (GONAL-f) for Medically Assisted Reproduction: A Systematic Review
Conclusion and Implications of Key FindingsOur analyses demonstrate low rates of OHSS and thromboembolism with GONAL-f. (Source: Advances in Therapy)
Source: Advances in Therapy - October 29, 2020 Category: Drugs & Pharmacology Source Type: research

Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching Analysis
AbstractIntroductionThe phase  3 ALCYONE study demonstrated significantly longer progression-free and overall survival (PFS/OS) and higher overall response rates (ORR) with daratumumab plus bortezomib, melphalan, and prednisone (D-VMP) versus VMP alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDM M). In Latin America, bortezomib- or thalidomide-based regimens remain standard of care (SoC) for this population. No head-to-head trials have compared D-VMP with SoC regimens used in Latin America.MethodsPropensity score matching (PSM) was used to control for baseline differences between patie...
Source: Advances in Therapy - October 29, 2020 Category: Drugs & Pharmacology Source Type: research

A Narrative Review of the Patient Journey Through the Lens of Non-communicable Diseases in Low- and Middle-Income Countries
AbstractLow- and middle-income countries (LMICs) are challenged with a disproportionately high burden of noncommunicable diseases (NCDs) and limited healthcare resources at their disposal to tackle the NCD epidemic. Understanding the patient journey for NCDs from the patients ’ perspective can help healthcare systems in these settings evolve their NCD care models to address the unmet needs of patients, enhance patient participation in their management, and progress towards better outcomes and quality of life. This paper aims to provide a theoretical framework outlining common touchpoints along the patient journey for...
Source: Advances in Therapy - October 29, 2020 Category: Drugs & Pharmacology Source Type: research

A Retrospective Cohort Study to Investigate the Incidence of Cachexia During Chemotherapy in Patients with Colorectal Cancer
We examined 150 patients with colorectal cancer who underwent first-line systemic chemotherapy between February  1, 2010 and August 31, 2016 at Shizuoka Cancer Center Hospital and Kurume University Hospital. Cancer cachexia was defined as >  5% weight loss or >  2% weight loss with a body mass index of
Source: Advances in Therapy - October 29, 2020 Category: Drugs & Pharmacology Source Type: research

Management of Cutaneous Calciphylaxis
AbstractCalciphylaxis is a deadly, painful disease with a 1-year mortality of up to 50%. The disease is commonly associated with patients with end-stage kidney disease (ESKD), but it can manifest in non-uremic patients as well. In patients who are undergoing dialysis, the incidence of calciphylaxis can range from 0.04% to 4%. The progressive arterial calcification seen in calciphylaxis can affect multiple body organs, including the skin, brain, lungs, and muscle. In cutaneous calciphylaxis, painful and non-healing nodules, plaques, and ulcers may appear, increasing morbidity for patients. Diagnosis can be difficult, and th...
Source: Advances in Therapy - October 29, 2020 Category: Drugs & Pharmacology Source Type: research

Mast Cells in Diabetes and Diabetic Wound Healing
AbstractMast cells (MCs) are granulated, immune cells of the myeloid lineage that are present in connective tissues. Apart from their classical role in allergies, MCs also mediate various inflammatory responses due to the nature of their secretory products. They are involved in important physiological and pathophysiological responses related to inflammation, chronic wounds, and autoimmune diseases. There are also indications that MCs are associated with diabetes and its complications. MCs and MC-derived mediators participate in all wound healing stages and are involved in the pathogenesis of non-healing, chronic diabetic f...
Source: Advances in Therapy - October 11, 2020 Category: Drugs & Pharmacology Source Type: research

Open-Label Assessment of the Effects of Itraconazole and Rifampicin on Balovaptan Pharmacokinetics in Healthy Volunteers
ConclusionsStrong modulators of CYP3A4 activity will significantly alter the PK of balovaptan, with the effect of CYP3A4 induction greater than that of inhibition. Caution should be taken when concomitantly dosing balovaptan with moderate or strong CYP3A4 inducers or strong CYP3A4 inhibitors.Trial Registration NumberNCT03579719; NCT03586726. (Source: Advances in Therapy)
Source: Advances in Therapy - October 11, 2020 Category: Drugs & Pharmacology Source Type: research

Responder Profile to Pharmaceutical-Grade Chondroitin Sulfate: An Analysis of the CONCEPT Trial
ConclusionThe treatment of OA with CS has the highest chance of success if administered in the early stage of the disease. Further research with other clinical outcomes should be carried out prior to widespread application of these findings.Trial RegistrationClinicalTrials.gov identifier, NCT03200288. (Source: Advances in Therapy)
Source: Advances in Therapy - October 11, 2020 Category: Drugs & Pharmacology Source Type: research

Effectiveness of Atorvastatin in the Treatment of Asymptomatic Heart Failure After Myocardial Infarction: A Clinical Study
AbstractIntroductionSilent heart failure after myocardial infarction has not been effectively treated. Atorvastatin has certain efficacy in the treatment of heart failure. Our clinical study aimed to investigate the effectiveness of atorvastatin in patients with asymptomatic heart failure after myocardial infarction.MethodsA total of 162 patients with asymptomatic heart failure after myocardial infarction in our hospital from August 2018 to August 2019 were randomly divided into the observation group (81 cases were treated with atorvastatin on the basis of routine therapy) and the control group (81 cases were treated with ...
Source: Advances in Therapy - October 11, 2020 Category: Drugs & Pharmacology Source Type: research

Bioequivalence Study Comparing Fixed-Dose Combination of Clopidogrel and Aspirin with Coadministration of Individual Formulations in Chinese Subjects Under Fed Conditions: A Phase I, Open-Label, Randomized, Crossover Study
This study is a randomized, single-center, open-label, three-sequence, three-period, two-treatment, crossover study conducted in healthy Chinese male and female subjects under fed conditions. Subjects were randomized to receive, in each period, a single dose of (1) a combination tablet containing 75-mg clopidogrel and 100-mg enteric ASA (test formulation) or (2) coadministration of one 75-mg clopidogrel tablet and one 100-mg enteric-coated ASA tablet (reference formulations) under fed conditions. Plasma samples were analyzed for ASA, salicylic acid, clopidogrel, and the clopidogrel metabolite SR26334. For ASA, the referenc...
Source: Advances in Therapy - October 11, 2020 Category: Drugs & Pharmacology Source Type: research

Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
ConclusionsEmpagliflozin improves liver steatosis and, more importantly, measures of liver fibrosis in patients with NAFLD without T2DM.Trial registrationClinicalTrials.gov identifier, IRCT20190122042450N1. (Source: Advances in Therapy)
Source: Advances in Therapy - October 11, 2020 Category: Drugs & Pharmacology Source Type: research

A New, Non-Invasive Scale for Steatosis Developed Using Real-World Data From Russian Outpatients to Aid in the Diagnosis of Non-Alcoholic Fatty Liver Disease
ConclusionOur non-invasive steatosis scale, St-index, can help physicians diagnose NAFLD in high-risk patients in the absence of ultrasound data. (Source: Advances in Therapy)
Source: Advances in Therapy - October 11, 2020 Category: Drugs & Pharmacology Source Type: research

Fact vs Fallacy: The Anti-Vaccine Discussion Reloaded
AbstractIn the light of the COVID-19 pandemic, anti-vaccine sentiments have been on the rise, with a recent seminal study on the development of anti-vaccine views in social media even making its way into Nature Communications. Yet, with the current scientific consensus being in overwhelming agreement over the safety and efficacy of vaccines, many scientists lose their grasp on the fears, concerns, and arguments that the opposition may hold. This paper discusses and evaluates vaccine-hesitant individuals on a socioeconomic, historical, and philosophical landscape. It also provides an analysis of common argumentative pattern...
Source: Advances in Therapy - October 11, 2020 Category: Drugs & Pharmacology Source Type: research

Single-Use (Disposable) Flexible Bronchoscopes: The Future of Bronchoscopy?
AbstractThe coronavirus disease (COVID-19) pandemic has highlighted the importance of reducing occupational exposure to severe acute respiratory syndrome coronavirus  2 (SARS-CoV-2). The reprocessing procedure for reusable flexible bronchoscopes (RFBs) involves multiple episodes of handling of equipment that has been used during an aerosol-generating procedure and thus is a potential source of transmission. Single-use flexible bronchoscopes (SUFBs) eliminate th is source. Additionally, RFBs pose a risk of nosocomial infection transmission between patients with the identification of human proteins, deoxyribonucleic aci...
Source: Advances in Therapy - October 11, 2020 Category: Drugs & Pharmacology Source Type: research

A Phase  I Placebo-Controlled Trial Comparing the Effects of Buprenorphine Buccal Film and Oral Oxycodone Hydrochloride Administration on Respiratory Drive
ConclusionsBBF did not significantly reduce respiratory drive at any dose compared with placebo, including at the maximum available prescription dose of 900  μg. Administration of oxycodone resulted in a significant dose-dependent decrease in respiratory drive. These data suggest that BBF may be a safer treatment option than full μ-opioid receptor agonists for patients with chronic pain.Trial RegistrationClinicalTrials.gov identifier, NCT03996694. (Source: Advances in Therapy)
Source: Advances in Therapy - October 11, 2020 Category: Drugs & Pharmacology Source Type: research

Management of Dyslipidemia in Individuals with Low-to-Moderate Cardiovascular Risk: Role of Nutraceuticals
AbstractCardiovascular diseases (CVDs) are the leading cause of premature deaths globally and in Ukraine. Dyslipidemia is a recognized risk factor for the development of CVD. Therefore, early detection and appropriate management of dyslipidemia are essential for the primary prevention of CVDs. However, currently, there is a lack of Ukraine-specific guideline recommendations focusing on the management of dyslipidemia in individuals with low-to-moderate CV risk, thus creating an urgent need for structured and easily implementable clinical recommendations/guidelines specific to the country. An expert panel of cardiologists, e...
Source: Advances in Therapy - October 11, 2020 Category: Drugs & Pharmacology Source Type: research

PSO-LONG: Design of a Novel, 12-Month Clinical Trial of Topical, Proactive Maintenance with Twice-Weekly Cal/BD Foam in Psoriasis
AbstractBackgroundPsoriasis vulgaris is commonly treated with topical corticosteroids and vitamin  D analogues. Although potent and super-potent topical corticosteroids are very effective at clearing psoriasis, with short-term reactive treatment durations, symptoms usually recur after treatment discontinuation, necessitating long-term disease management strategies. A foam formulation of calcipo triol and betamethasone dipropionate (Cal/BD foam), consisting of calcipotriol 50 μg/g and betamethasone dipropionate 0.5 mg/g, is approved for the daily treatment of psoriasis for up to 4 weeks. Here, we desc...
Source: Advances in Therapy - October 11, 2020 Category: Drugs & Pharmacology Source Type: research

Correction to: Pharmacokinetics and Dialyzability of a Single Oral Dose of Amenamevir, an Anti-Herpes Drug, in Hemodialysis Patients
In the original article, there is incorrect text has published as “The hemodialysis clearance, elimination fraction percentage, and amount of amenamevir removed were 37.8 mL/min, 28.1%, and 132.0 μg, respectively”. (Source: Advances in Therapy)
Source: Advances in Therapy - October 11, 2020 Category: Drugs & Pharmacology Source Type: research

Adherence to the EAU Guideline Recommendations for Local Tumor Treatment in Penile Cancer: Results of the European PROspective Penile Cancer Study Group Survey (E-PROPS)
ConclusionPatients with PeCa are best treated by experienced physicians, in centers with a high number of cases, which also offer a wide range of local tumor therapy. This could be offered in reference centers. (Source: Advances in Therapy)
Source: Advances in Therapy - October 10, 2020 Category: Drugs & Pharmacology Source Type: research

Real-World Evidence to Contextualize Clinical Trial Results and Inform Regulatory Decisions: Tofacitinib Modified-Release Once-Daily vs Immediate-Release Twice-Daily for Rheumatoid Arthritis
ConclusionThese results demonstrate the value of real-world evidence from complementary data sources in understanding the impact of medication adherence with a QD formulation in clinical practice. These analyses were suitable for regulatory consideration as an important component of evidence for the comparability of tofacitinib MR 11  mg QD vs IR 5 mg BID in patients with RA.Trial RegistrationClaims database study: ClinicalTrials.gov identifier NCT04018001, retrospectively registered July 12, 2019. Corrona US RA Registry study: ClinicalTrials.gov identifier NCT04267380, retrospectively registered February 12, 202...
Source: Advances in Therapy - October 9, 2020 Category: Drugs & Pharmacology Source Type: research

Glucocorticoid and Breviscapine Combination Therapy Versus Glucocorticoid Alone on Sudden Sensorineural Hearing Loss in Patients with Different Audiometric Curves
AbstractIntroductionWe aimed to retrospectively analyze the therapeutic outcomes of using glucocorticoid combined with a vasodilator, breviscapine, versus glucocorticoid alone in patients with sudden sensorineural hearing loss (SSNHL) and to explore the impact on different audiometric curves.MethodsData from 154 patients were collected between January 2017 and December 2018. Patients received treatments of either glucocorticoid combined with breviscapine (GC  + Bre) or glucocorticoid alone (GC). These two groups were stratified into low frequencies SSNHL (LF-SSNHL), high frequencies SSNHL (HF-SSNHL), all freq...
Source: Advances in Therapy - October 9, 2020 Category: Drugs & Pharmacology Source Type: research

A Retrospective Observational Analysis of Overall Survival with Sipuleucel-T in Medicare Beneficiaries Treated for Advanced Prostate Cancer
ConclusionThis analysis suggests use of sipuleucel-T at any time was associated with improved OS compared with ASPI use alone. Of note, these analyses are intended as descriptive rather than definitive as this dataset contains limited data on key clinical factors. While selection bias is a risk in secondary claims data, this research provides important insight into real-world treatment outcomes. (Source: Advances in Therapy)
Source: Advances in Therapy - October 6, 2020 Category: Drugs & Pharmacology Source Type: research

Effect of Perindopril/Indapamide on Cerebral Blood Flow in Middle-Aged, Treatment-Na ïve Patients with Hypertension
This study evaluated the impact of a perindopril arginine/indapamide (Pa/I) single-pill combination (SPC) on CBF in middle-aged patients.MethodsA total of 22 treatment-na ïve patients with essential hypertension and at least one hypertension-mediated organ damage and 41 healthy controls were enrolled. At baseline, all participants underwent brain magnetic resonance imaging (MRI); patients with hypertension underwent an additional MRI at end of follow-up. Arterial sp in labeling (ASL) was used to calculate CBF in the frontal lobe cortical plate. Patients with hypertension received once-daily Pa/I 5 mg/1.25 mg...
Source: Advances in Therapy - October 6, 2020 Category: Drugs & Pharmacology Source Type: research

Multiple-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites and the Pharmacodynamic and Pharmacokinetic Interactions with Pseudoephedrine, a Sympathomimetic Agent, in Healthy Subjects
ConclusionConcomitant administration of ozanimod with PSE, a sympathomimetic agent, did not potentiate the effects on blood pressure.Trial RegistrationNCT03644576. (Source: Advances in Therapy)
Source: Advances in Therapy - October 5, 2020 Category: Drugs & Pharmacology Source Type: research

24-Hour Serial Spirometric Assessment of Once-Daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-Daily Budesonide/Formoterol in Patients with COPD: Analysis of the FULFIL Study
AbstractIntroductionFew studies have utilized 24-h serial spirometry to compare the effects of inhaled chronic obstructive pulmonary disease (COPD) therapies on lung function. The FULFIL study previously reported significant lung function improvements with once-daily single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus twice-daily single-inhaler budesonide/formoterol (BUD/FOR) in patients with symptomatic COPD at risk of exacerbations.MethodsThis prespecified analysis evaluated 24-h serial spirometry data from a subgroup of 406 patients in FULFIL. BUD/FOR twice-daily dosing was maintained during 2...
Source: Advances in Therapy - October 2, 2020 Category: Drugs & Pharmacology Source Type: research

A Systematic Review of the Clinical Efficacy of Treatments in Relapsed or Refractory Diffuse Large B Cell Lymphoma
ConclusionsThese findings highlight the paucity of published RCTs to establish the comparative efficacy of treatments for transplant-ineligible R/R DLBCL and lack of standard of care in this setting. (Source: Advances in Therapy)
Source: Advances in Therapy - September 30, 2020 Category: Drugs & Pharmacology Source Type: research

Prolonged Fetal Heart Rate Decelerations in Labor: Can We Reduce Unplanned Primary Cesarean Sections in This Group?
ConclusionOur results indicate that the practice of placing patients on fetal monitor upon arrival to the operating room prior to performing crash cesarean delivery could reduce the rate of primary cesarean deliveries performed for prolonged decelerations in labor. When fetal heart tones have returned to baseline upon arrival in the operating room, the decision to proceed with cesarean delivery can be reconsidered. However, many clinical factors must be taken into consideration, and the decision to proceed is ultimately at the discretion of the obstetrics provider. (Source: Advances in Therapy)
Source: Advances in Therapy - September 15, 2020 Category: Drugs & Pharmacology Source Type: research

Perspectives on the Early Quality of Evidence Guiding the Therapeutic Management of SARS-CoV-2: A Systematic Literature Review
ConclusionEstablishing consensus with respect to the end points to be assessed for respiratory viruses may enhance the quality of evidence in case of future pandemics. The systematic review highlighted the lacuna and methodologic deficiency in early clinical evidence and included an update on different therapeutic management guidelines. Further clinical evidence from the ongoing trials may lead to evolution of treatment guidelines with the addition of more therapeutic options. (Source: Advances in Therapy)
Source: Advances in Therapy - September 15, 2020 Category: Drugs & Pharmacology Source Type: research

Evaluation of the Physico-Chemical and Biological Stability of SB8 (Aybintio), a Proposed Biosimilar to Bevacizumab, Under Ambient and In-Use Conditions
ConclusionUnder the studied aspetic extreme conditions, SB8 was stable. Our data may support advanced SB8 preparation and may help prevent SB8 wastage because of exceptional temperature excursions or unused product. Sterility assurance is the responsibility of the user and is of utmost importance when opened or diluted SB8 is not immediately used. (Source: Advances in Therapy)
Source: Advances in Therapy - September 15, 2020 Category: Drugs & Pharmacology Source Type: research

Folic Acid Supplementation in Patients with Elevated Homocysteine Levels
ConclusionFolic acid supplementation should be recommended to any patient who has an elevated Hcy level, and this level should be measured and treated at an early age, since folic acid is easily obtained and may likely reduce vascular disease and other deleterious pathologic processes in high-risk populations. (Source: Advances in Therapy)
Source: Advances in Therapy - September 15, 2020 Category: Drugs & Pharmacology Source Type: research

Advances in Topical Hemostatic Agent Therapies: A Comprehensive Update
AbstractSevere hemorrhage causes significant metabolic and cellular dysfunction secondary to deficient tissue perfusion and oxygen delivery. If bleeding continues, hemodynamic destabilization, hypoxemia, multiple organ failure, and death will occur. Techniques employed to promote hemostasis include surgical suture ligatures, cautery, chemical agents, self-assembling nanoparticles, and physical methods, like mechanical pressure. Improved understanding of the natural clotting cascade has allowed newly designed agents to become more targeted for clinical and military use. Topically-applied hemostatic agents have enormous clin...
Source: Advances in Therapy - September 15, 2020 Category: Drugs & Pharmacology Source Type: research

Non-Pharmacological Management of Painful Peripheral Neuropathies: A Systematic Review
ConclusionsFuture RCTs should be conducted to shed more light in the use of non-pharmacological approaches in patients with PNP. (Source: Advances in Therapy)
Source: Advances in Therapy - September 15, 2020 Category: Drugs & Pharmacology Source Type: research

Adverse Drug Events Observed with the Novel Sodium/Glucose Co-Transporter 2 Inhibitor Ipragliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Studies
ConclusionsThe current analysis showed ipragliflozin to be associated with significantly higher genital infection rates compared to placebo, whereas no significant difference was observed compared to the other adverse drug events in these patients with T2DM. In addition, hypoglycemia was also not significantly different following sensitivity analysis. (Source: Advances in Therapy)
Source: Advances in Therapy - September 15, 2020 Category: Drugs & Pharmacology Source Type: research

Rates and Anticoagulation Treatment of Known Atrial Fibrillation in Patients with Acute Ischemic Stroke: A Real-World Study
ConclusionsThis study revealed a low known AF rate, low OACs use rate and low rate of meeting the guideline-based criteria for OACs in AIS patients with AF in the northwest region of China. These findings indicated the importance of AF as a public health problem in China. (Source: Advances in Therapy)
Source: Advances in Therapy - September 15, 2020 Category: Drugs & Pharmacology Source Type: research

Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting
ConclusionsOnce-weekly semaglutide 0.5  mg and 1 mg were considered dominant (more effective and less costly) versus sitagliptin 100 mg and dulaglutide 1.5 mg for the treatment of patients with type 2 diabetes with inadequate glycemic control on oral anti-hyperglycemic medications and are likely to be a good use of healthcare resourc es in the Spanish setting. (Source: Advances in Therapy)
Source: Advances in Therapy - September 15, 2020 Category: Drugs & Pharmacology Source Type: research

Preparing the Burns Unit to Accommodate Vaginal Delivery and Cesarean Section for Pregnant Women with COVID-19: A Successful Experience from Jordan
(Source: Advances in Therapy)
Source: Advances in Therapy - September 15, 2020 Category: Drugs & Pharmacology Source Type: research

Correction to: Sulodexide in the Treatment of Chronic Venous Insufficiency: Results of the All-Russian Multicenter ACVEDUCT Program
In the original article, the “Duration, Types of Therapy and Dynamics of Improvements” topic published incorrectly. (Source: Advances in Therapy)
Source: Advances in Therapy - September 15, 2020 Category: Drugs & Pharmacology Source Type: research

The Economic Value of Improved Productivity from Treatment of Chronic Hepatitis C Virus Infection: A Retrospective Analysis of Earnings, Work Loss, and Health Insurance Data
AbstractIntroductionPatients with chronic hepatitis C virus infection (HCV) may incur significant indirect costs due to health-related work loss. However, the impact of curative HCV therapy on work productivity is not well characterized. We estimated the economic value of improved productivity following HCV treatment.MethodsAdults diagnosed with HCV infection (Optum Healthcare Solutions data; Q1 1999 to Q1 2017) were stratified into two cohorts: (1) treated cohort, patients who received HCV therapy and (2) untreated cohort, therapy-na ïve patients. For the treated cohort, the index date was set at the end of the post-...
Source: Advances in Therapy - September 13, 2020 Category: Drugs & Pharmacology Source Type: research

Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Na ïve Patients with Compensated Cirrhosis
In the original article, there is an error in Fig.  1. (Source: Advances in Therapy)
Source: Advances in Therapy - September 10, 2020 Category: Drugs & Pharmacology Source Type: research

Correction to: Unlocking the Value of Anti-TNF Biosimilars: Reducing Disease Burden and Improving Outcomes in Chronic Immune-Mediated Inflammatory Diseases: A Narrative Review
In the original article, under the “Access to treatment” heading. (Source: Advances in Therapy)
Source: Advances in Therapy - September 10, 2020 Category: Drugs & Pharmacology Source Type: research

Increased Healthcare Resource Utilization and Direct and Indirect Costs in Patients with Depression and Comorbid Overactive Bladder: Evidence From a Retrospective, Matched Case –Control Cohort Analysis
This study sought to compare healthcare resource utilization (HCRU), costs, and workplace productivity among patients with depression, with and without overactive bladder (OAB).MethodsThis retrospective, case –control cohort analysis compares HCRU, costs, and workplace productivity among propensity score matched patients with depression and OAB (case cohort) and patients with depression without OAB (control cohort). Patients were aged 18 years or older, insured/on Medicare, and had diagnosed depressio n and an antidepressant medication claim pre index. First OAB-related event was index for cases; controls were a...
Source: Advances in Therapy - September 9, 2020 Category: Drugs & Pharmacology Source Type: research

The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence
AbstractWith the increasing availability of biosimilars, the practice of switching therapies for non-medical reasons between an originator biologic and an analogous biosimilar has become more common. The evidence to support this practice mostly comes from single-switch randomized controlled trials (RCTs) and real-world (RW) evidence studies. However, as more biosimilars of the same originator enter the market, multiple switching events between originators and biosimilars is becoming a reality, despite limited evidence to support the efficacy and safety of such practice. Some countries have established guidelines, policies,...
Source: Advances in Therapy - September 9, 2020 Category: Drugs & Pharmacology Source Type: research

Correction to: The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants
In the original article, the reference 4 has been published and cited  incorrectly. (Source: Advances in Therapy)
Source: Advances in Therapy - September 9, 2020 Category: Drugs & Pharmacology Source Type: research

Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase  3 FRESCO Trial
ConclusionsThe most common treatment-related grade  ≥ 3 AEs were hypertension, HFSR, and proteinuria. The treatment-related TEAE profile of fruquintinib in Chinese patents with mCRC was comparable among different subgroups and consistent with that reported in the overall population.Trial Registration: Clinical Trials identifier NCT02314819. (Source: Advances in Therapy)
Source: Advances in Therapy - September 7, 2020 Category: Drugs & Pharmacology Source Type: research

Relation of High Lipoprotein  ( a ) Concentrations to Platelet Reactivity in Individuals with and Without Coronary Artery Disease
AbstractIntroductionLipoprotein  (a) [Lp(a)] is a risk factor for coronary artery disease (CAD). To the best of our knowledge, this is the first study addressing the relationship between Lp(a) and platelet reactivity in primary and secondary prevention.MethodsLp(a) was evaluated in 396 individuals with (82.3%) and without (17.7%) obstructive CAD. The population was divided into two groups according to Lp(a) concentrations with a cutoff value of 50  mg/dL. The primary objective was to evaluate the association between Lp(a) and adenosine diphosphate (ADP)-induced platelet reactivity using the VerifyNow ™ P2Y1...
Source: Advances in Therapy - September 4, 2020 Category: Drugs & Pharmacology Source Type: research